Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Bile Duct Neoplasms

ClinicalTrials.gov lists 256 trials for Bile Duct Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 27.

MeSH D001650 Neoplasms Neoplasm C04 C06
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 48 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 70 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 18 Phase 4 Phase 4 10 Not applicable Not applicable 43 Observational Observational 45 Phase 1 Phase 1 48 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 70 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 18 Phase 4 Phase 4 10 Not applicable Not applicable 43 Observational Observational 45

Trials per phase

1 more section with rows

250 of the 256 trials are tagged with Bile Duct Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Bile Duct Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Bile Duct Neoplasms trials start? (31)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 19

1994: 1 trials (Phase 1 1) 1997: 3 trials (Phase 1 3) 1998: 8 trials (Phase 2 2, Phase 1 6) 1999: 7 trials (Phase 2 5, Phase 1 2) 2000: 9 trials (Observational 3, Phase 2 1, Phase 1/2 1, Phase 1 4) 2001: 7 trials (Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2002: 5 trials (Phase 2 4, Phase 1 1) 2003: 4 trials (Phase 2 2, Phase 1 2) 2004: 10 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 3) 2005: 8 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 2) 2006: 6 trials (Phase 4 1, Phase 3 2, Phase 2 3) 2007: 10 trials (Observational 1, Not applicable 1, Phase 3 3, Phase 2 4, Phase 1 1) 2008: 9 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 2) 2009: 8 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 1, Phase 2 2, Phase 1 1) 2010: 6 trials (Not applicable 1, Phase 4 1, Phase 2 4) 2011: 6 trials (Observational 3, Not applicable 1, Phase 3 1, Phase 2 1) 2012: 4 trials (Observational 1, Not applicable 1, Phase 2/3 1, Phase 1 1) 2013: 9 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2014: 10 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 2 5, Phase 1/2 1) 2015: 7 trials (Not applicable 2, Phase 3 1, Phase 2/3 1, Phase 2 1, Phase 1 2) 2016: 9 trials (Observational 2, Not applicable 4, Phase 4 1, Phase 3 1, Phase 2 1) 2017: 12 trials (Observational 2, Not applicable 1, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2018: 8 trials (Observational 1, Not applicable 1, Phase 2/3 1, Phase 2 2, Phase 1/2 2, Phase 1 1) 2019: 10 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2 3, Phase 1 1) 2020: 19 trials (Observational 7, Not applicable 5, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2021: 10 trials (Observational 3, Not applicable 3, Phase 1/2 1, Phase 1 3) 2022: 10 trials (Observational 2, Not applicable 2, Phase 2 2, Phase 1/2 2, Phase 1 2) 2023: 13 trials (Observational 3, Not applicable 3, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 2024: 13 trials (Observational 2, Not applicable 5, Phase 2 3, Phase 1/2 1, Phase 1 2) 2025: 7 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 2 2, Phase 1/2 1, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 4
2025 7
2024 13
2023 13
2022 10
2021 10
2020 19
2019 10
2018 8
2017 12

Showing 10 of 31 earlier years.

Start your 14-day trial Email me all 31 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 6 trials starting in 2026 and about 7 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 26 trials still running at the 2026-10-09 snapshot; registered median of 39 months across 153 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Bile Duct Neoplasms trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 48
Phase 1/2 16
Phase 2 70
Phase 2/3 5
Phase 3 18
Phase 4 10
Not applicable 43
Observational 45
Expanded access 1

How many Bile Duct Neoplasms trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 5
Recruiting 30
Enrolling by invitation 1
Active, not recruiting 11
Completed 128

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Bile Duct Neoplasms trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 27
National Institutes of Health Clinical Center (CC) 4
Merck Sharp & Dohme LLC 3

Which drugs are being tested for Bile Duct Neoplasms? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
"Capecitabine" 20
OXALIPLATIN 13
Calcium Leucovorin 9
PEMBROLIZUMAB 8
Irinotecan 7

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Gemcitabine/Gemzar 28
Cisplatin 1 15
Fluorouracile 12
1- Erlotinib 7
Radiation Therapy 7

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Bile Duct Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Cholangitis 107 8
Sepsis 67 20
Pyrexia 61 9
Platelet count decreased 58 9
Abdominal pain 57 17

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Bile Duct Neoplasms? (599)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma. Journal of hepatology 2026 Yes
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial. The lancet. Gastroenterology & hepatology 2026 Yes
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial. The lancet. Gastroenterology & hepatology 2026 Yes
Survival Outcomes of Microwave Ablation Compared with Repeat Liver Resection in the Treatment of Recurrent Intrahepatic Cholangiocarcinoma. Radiology 2026 Yes
Locoregional Treatment Options for Locally Advanced Intrahepatic Cholangiocarcinoma. Journal of the National Comprehensive Cancer Network : JNCCN 2025 Yes

Showing 5 of 599 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages